Christopher Shen, MD is a Managing Director and head of U.S. healthcare investing at Vertex Management. Dr. Shen specializes in investments in biopharmaceutical and medical device companies. Previously, Dr. Shen worked at Essex Woodlands Health Ventures, a healthcare-focused venture capital and private equity firm. Prior to joining EWHV, he worked at New Enterprise Associates, one of the largest, diversified venture capital firms. Previously, Dr. Shen held the position of Senior Design Engineer at Guidant Corporation's Neurovascular Venture, an internal start-up, where he invented and commercialized a minimally-invasive therapy for the treatment of acute ischemic stroke. Dr. Shen also worked in Japan as a Design Engineer for Pfizer, Inc.’s Strategic Innovation Group, an internal medical technology incubator.
Dr. Shen is the U.S. Executive Director of the Singapore Stanford Biodesign Program and a Consulting Associate Professor of Medicine at Stanford University, focusing on medical technology innovation. He has nine patents issued and several pending in the fields of interventional neuroradiology and interventional cardiology.
Dr. Shen received his Doctor of Medicine from the Stanford School of Medicine, his Master of Business Administration from Stanford Graduate School of Business, and a Master of Biomechanical Engineering from the Stanford School of Engineering. He received his Bachelor of Science in Biological Sciences from Stanford University.